• Vial’s IL-13 x TSLP is designed to deliver breadth, depth, and durability of Type 2 disease control in a single half-life-extended antibody • Phase 1a data in healthy volunteers (15–800 mg IV) support progression into patients, with pharmacokinetics that could support twice-yearly (Q6M) dosing • Phase 1b study will evaluate safety, tolerability, pharmacokinetics, and FeNO-based proof-of-mechanism in patients with mild-to-moderate asthma • Interim Phase 1b data readout expected in H1 2027
October 5, 2026
· 1 min read
